Amira Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Novira Therapeutics, Inc.

Tempest Therapeutics, Inc.

Inception 2, Inc.

Merck + Co., Inc.

Inception Orion, Inc.

Brickell Biotech, Inc.

Autoimmune Pharma LLC

Nicholas Simon Stock

John Howard Hutchinson

Brian Andrew Stearns

Ryan Christopher Clark

Yen Truong

Jason Duarte Jacintho

Deborah Volkots

Jeffrey Roger Roppe

Yalda Mostofi Bravo

Thomas Jon Seiders

Jeannie M Arruda

Austin Chih-Yu Chen

Jill Melissa Scott

Bowei Wang

Petpiboon Peppi Prasit

Jill Melissa Baccei

Jasmine Eleanor Zunic

Lucy Xiumin Zhao

Timothy Andrew Parr

Mark Moran

Jillian Frances Evans

Mustapha Haddach

Heather Renee Coate

Bijan Pedram

Austin Chen

Yiwei Li

Kevin Schaab

William K Hagmann

Nicholas D Smith

Benito Munoz

Ping Liu

Linus S Lin

Thomas S Reger

Richard A Mumford

Melissa Rewolinski

Christopher David King

David Nathan Zalatan

Yem Pham Truong

Yen Pham Truong

Kevin Murray Schaab

Jason Jacintho

The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

Triazolone compounds and uses thereof

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Sulfide alkyl compounds for HBV treatment

Pyridyl reverse sulfonamides for HBV treatment

The invention disclosed herein is directed to compounds of Formula I [Formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. 

Pyrazolone compounds and uses thereof

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

Autotaxin inhibitors and uses thereof

The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic&#x3b4; leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPAR&#x3b1; and PPAR&#x3b4;. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a therapeutically effective amount of a dual antagonist of PPAR&#x3b1; and PPAR&#x3b4;. 

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Compounds as lysophosphatidic acid receptor antagonists

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist.

Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

Growing community of inventors

San Diego, CA, United States of America

Nicholas Simon Stock